Combining Low-Dose PT-141 Nasal Spray With Viagra: Synergistic Erectile Effect
Low-dose intranasal PT-141 combined with sildenafil produced synergistic erectile effects in ED patients — combining brain-acting (desire) with peripheral-acting (blood flow) mechanisms for superior results.
Quick Facts
What This Study Found
Co-administration of low-dose intranasal PT-141 (melanocortin agonist) with sildenafil (PDE5 inhibitor) produced synergistic erectile responses in ED patients — combining central desire/arousal with peripheral vasodilation for superior outcomes.
Key Numbers
How They Did This
RCT study on pt-141, sexual-health.
Why This Research Matters
Relevant for pt-141, sexual-health, clinical-trials.
The Bigger Picture
Advances peptide research with clinical implications.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding Co-administration of low-dose intranasal PT-141 (melanocortin agonist) with sildenafil (PDE5 inhibitor) produced synergistic erectile responses in ED
- Evidence Grade:
- moderate evidence.
- Study Age:
- Published in 2005.
- Original Title:
- Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.
- Published In:
- Urology, 65(4), 755-9 (2005)
- Authors:
- Diamond, L E(4), Earle, D C(3), Garcia, W D, Spana, C
- Database ID:
- RPEP-01028
Evidence Hierarchy
Frequently Asked Questions
What was studied?
Combining Low-Dose PT-141 Nasal Spray With Viagra: Synergistic Erectile Effect
What was found?
Low-dose intranasal PT-141 combined with sildenafil produced synergistic erectile effects in ED patients — combining brain-acting (desire) with peripheral-acting (blood flow) mechanisms for superior results.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01028APA
Diamond, L E; Earle, D C; Garcia, W D; Spana, C. (2005). Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.. Urology, 65(4), 755-9.
MLA
Diamond, L E, et al. "Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.." Urology, 2005.
RethinkPeptides
RethinkPeptides Research Database. "Co-administration of low doses of intranasal PT-141, a melan..." RPEP-01028. Retrieved from https://rethinkpeptides.com/research/diamond-2005-coadministration-of-low-doses
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.